ClinicalTrials.Veeva

Menu

Effect of Inhalation of Low Dose CO2 on Exercise Performance at High Altitude

S

State Key Laboratory of Respiratory Disease

Status

Completed

Conditions

Inhalation; Gas
Acute Mountain Sickness
High Altitude

Treatments

Other: Exercise under inhalation ambient air
Drug: Exercise under inhalation CO2

Study type

Interventional

Funder types

Other

Identifiers

NCT05798416
2020 No.37

Details and patient eligibility

About

High altitude (>2400 m) is associated with decreased atmosphere pressure leading to hypoxia which in turn impairs exercise capacity and causes acute mountain sickness (AMS). It is noted that adding CO2 might be beneficial to improve hypoxia and exercise performance at high altitude. However, no device is currently available that can supply a constant low dose of CO2 during free movement at high altitude. We have recently invented a portable device which is small and light enough for supplement of low dose CO2 during field exercise at high altitude.

Full description

Objective: To determine whether the supplement of low-dose CO2 by the novel device could improve exercise performance at high altitude.

Methods: The lowlanders (<500m) who have no history of travelling to high altitude (>1000m) a year before the study will be recruited. And the subjects who are high-altitude residents and have not left high altitude over the last twelve months will also be recruited for the study. Subjects will be randomly and blindly given either CO2 mixed with air or air alone during endurance shuttle walking test (ESWT). Blood gases will be measured before and after inhalation of CO2. ESWT time, ventilation per minute (VE), blood oxygen saturation (SPO2), and end-tidal CO2 concentration (ETCO2) will be measured during exercise and will be compared during inhalation of CO2 and during inhalation of ambient air.

Enrollment

28 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Healthy lowlanders (<500m) who have no history to travel to high altitude (>1000m) a year before the study.
  2. Healthy high altitude (4500m) residents who have not left the inhabited area over the last twelve months before the study.

Exclusion criteria

  1. Subjects with cardiovascular diseases, respiratory diseases and neuromuscular diseases which could affect exercise.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

28 participants in 2 patient groups, including a placebo group

Exercise under inhalation of CO2
Active Comparator group
Description:
Subjects will perform shuttle walk test under inhalation of low concentration of CO2 supplied by a novel device at high altitude.
Treatment:
Drug: Exercise under inhalation CO2
Exercise under inhalation of ambient air
Placebo Comparator group
Description:
Subjects will perform shuttle walk test under inhalation of ambient air at high altitude.
Treatment:
Other: Exercise under inhalation ambient air

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems